Organization
Dyax Corp.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Dyax Corp.
... U.S., Todd served as Executive Vice President and Chief Commercial Officer of Dyax Corp., where he was responsible for global commercial strategy and oversight of ...
... $164 million, primarily due to an increase in royalty streams acquired with Dyax and SENSIPAR royalties.Operating results- Operating income was $709 million (Q3 2016: operating ...
... Reported positive topline data for SHP643 (lanadelumab), which was acquired with Dyax Corp. (Dyax), an investigational treatment that reduced Hereditary Angioedema (HAE) monthly attack rate ...
... Results include Baxalta Inc. (Baxalta) (acquired on June 3, 2016) and Dyax Corp. (Dyax) (acquired on January 22, 2016), unless otherwise noted. Percentages compare to ...
... Results include Baxalta Inc. (Baxalta) (acquired on June 3, 2016) and Dyax Corp. (Dyax) (acquired on January 22, 2016), unless otherwise noted. Percentages compare to ...
... to achieve the strategic objectives with respect to Shire's acquisition of NPS, Dyax or Baxalta may adversely affect Shire's financial condition and results of operations; ...
... compared with Q3 2015, primarily due to the inclusion of Baxalta and Dyax operating costs, and costs related to licensing SHP647. Non GAAP R&D increased ...
... objectives with respect to Shire's acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. ('Dyax') may adversely affect the company's financial condition and results of operations; ...
... in both pre-approval and in commercial stages of product development. She joined Dyax in 2009 and most recently served as Vice President, Associate General Counsel ...
... joining Santhera Todd Bazemore served as EVP & Chief Commercial Officer at Dyax Corp. where he was responsible for global commercial strategy and oversaw all ...
... objectives with respect to Shire's acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. ("Dyax") may adversely affect the company's financial condition and results of operations;the ...
... objectives with respect to Shire's acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. ("Dyax") may adversely affect the company's financial condition and results of operations;the ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤